Novartis Employee Kicks Back filing Kickback Whistleblower Lawsuit
July 7, 2014
The whistleblower lawsuit was filed in New Jersey by Min Amy Guo, the former executive director of Novartis’ Health Economics and Outcomes Research Group, according to the Star-Ledger. Guo claims in her lawsuit that she was fired last year after suggesting the way Novartis proposed awarding a contract to McKesson for a study of cancer drug Afinitor “presented a conflict of interest and an appearance of kickbacks under the disguise of research.”
What? An employee was fired for pointing out unethical or illegal behavior? Where have we seen that before?
But wait didn’t Novartis already, four years ago, promise to live by a new integrity code? Where have we seen that before a company signing integrity codes with The DOJ only to disregard them as no more a deterrent than a parking ticket?
Novartis has several times before been accused of using creative thinking to push its drugs. In 2010, it paid $422 million in fines and civil penalties to settle allegations that it offered kickbacks to doctors to increase prescriptions of its blood pressure drugs Diovan, Exforge and Tekturna. That settlement included a 5-year “corporate integrity” agreement which it is presumably still following
Creative thinking regarding kickbacks? And where have we seen that before where the company creatively killed children?
One trend we can predict:
Whistleblower lawsuits will increase.
The Sociopathic Buisness Model™ points out corporate and governmental unethical and illegal behavior is entrenched in both systems.
Both sides always doing what they always did will end with corrupt companies paying billion dollar fines; and, the corrupt government’s refusal to actually deter fraud or show transparency where the billion dollar fines are allocated will do little to fix the badly broken system.
Hey Mr. DOJ How About Playing a Different Song? Corporate Integrity Agreements signed by companies who have already proven to lack integrity do not work.